Clinical Chemistry Study Reports on Use of T2MR to Evaluate Hemostasis in Whole Blood

T2 Biosystems today announced that scientists from the University of
Pennsylvania and T2 Biosystems have published a manuscript in Clinical
Chemistry evaluating the use of T2MR technology for studying
comprehensive hemostasis in whole blood. Titled "T2 magnetic resonance:
a diagnostic platform for studying integrated hemostasis in whole blood
- proof of concept," the publication explores the potential of T2MR, an
innovative and proprietary magnetic resonance-based diagnostic
technology platform that may offer a rapid, sensitive and simple
alternative to the current clinical standard in diagnostics.

"Existing approaches for measuring a panel of hemostasis parameters
including platelet activity typically require multiple and often
relatively complex platforms, large volumes of blood and can take
several hours to provide results. These limitations can make it
difficult to obtain many of the rapid and accurate assessments of
hemostasis that are often needed to effectively guide therapeutic
decisions," said study lead author Douglas B. Cines, MD, Professor of
Pathology and Laboratory Medicine and Director of the Special
Coagulation Laboratory, Perelman School of Medicine at the University of
Pennsylvania. "These new results suggest that T2MR has the potential to
address this need by providing more rapid and sensitive identification
of patients at risk for thrombosis or bleeding using a single,
simple-to-use approach."

The T2MR diagnostic technology platform is a research and
investigational product that has potential to provide a comprehensive
assessment of hemostatic parameters on a single instrument in less than
20 minutes using very small volumes of blood(0.04 ml). The technology
works by measuring how water molecules react in the presence of magnetic
fields and is highly sensitive to changes in a blood sample (such as
clot formation, stabilization or dissipation), which alter the magnetic
resonance signal and enable identification of clinically relevant
hemostasis changes.

About the Study

In the research study, T2MR signals of clotting samples were compared
with standard reference methods for hematocrit, prothrombin time, clot
strength and platelet activity. Results suggest that the T2MR platform
may be used for more precise and accurate measurements of hematocrit,
clotting time, clot strength and platelet function. This paper builds on
research published in December 2013 in the hematology journal Blood, in
which T2 Biosystems and University of Pennsylvania researchers announced
the discovery of a novel blood clot structure. The Clinical Chemistry
study compares T2MR signals of clotting samples with images produced by
scanning electron microscopy to demonstrate how researchers were able to
apply T2MR methodology to reveal the conditions under which this unique
blood clot appeared. Further investigations will determine the clinical
potential of using this T2MR signature to identify patients at risk of
thrombosis or bleeding or stroke and heart attack victims where such
clots may be less responsive to medications.

"These data provide further evidence that support T2MR's ability to
provide critical hemostasis measures both clinically and in the
identification of new biomarkers and therapeutic targets," said Tom
Lowery, Ph.D., Chief Scientific Officer of T2 Biosystems and co-author
of the study.

One future application of T2MR's more rapid potential assessment
capabilities is in trauma settings involving impaired hemostasis, a
potentially life-threatening condition in which a patient is unable to
form blood clots to stabilize excessive bleeding. Research has shown
that mortality of trauma patients with symptoms of impaired hemostasis
can be reduced from 45 to 19 percent with more rapid detection and
delivery of therapy. Approximately 25 percent of trauma patients have
impaired hemostasis that currently often goes undetected.

T2MR is currently intended for research use only. It is not intended for
use in diagnostic procedures.

About T2 Biosystems

T2 Biosystems is an in vitro diagnostics company that is using
its T2 Magnetic Resonance platform, or T2MR, to develop a broad set of
applications aimed at lowering mortality rates, improving patient
outcomes and reducing the cost of healthcare by helping medical
professionals make targeted treatment decisions earlier. T2MR enables
rapid detection of pathogens, biomarkers and other abnormalities in a
variety of unpurified patient sample types, including whole blood, and
can detect cellular targets at limits of detection as low as one
colony-forming unit per milliliter, or CFU/mL. T2 Bio's initial
development efforts utilizing T2MR target sepsis and hemostasis, which
are areas of significant unmet medical need in which existing therapies
could be more effective with improved diagnostics.